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Objective: To evaluate the potential impacts of exogenous administration of murine recombinant interleukin-I2 (IL-12) 
on multiplication of Mycobacterium tuberculosis and M. avium complex (MAC) in  murine models. 
Methods: Swiss or beige mice were infected intravenously with M. tuberculosis H37Rv or MAC respectively, and were 
treated by subcutaneous injection with various doses of IL-12, either alone or in combination with chemotherapy. 
Effectiveness of treatment was assessed by the enumeration of CFUs in  the spleens and lungs, together with other 
indicators. 
Results: Multiplication of M. tuberculosis was reduced by IL-12 in  a dose-dependent manner if the treatment began at 
day 1, whereas no statistically significant suppression was observed if the treatment began at day 14. Combination with 
IL-I2 did not enhance the bactericidal activity of antituberculosis chemotherapy. The growth curves of MAC in IL-12- 
treated mice were almost identical t o  those of untreated controls, indicating that IL-12 did not affect the multiplication 
of MAC in  beige mice. In both experiments, the dosing of IL-12 approached levels of severe toxicity for the mouse strains 
used. 
Conclusions: IL-12 had a positive affect on early multiplication of M. tuberculosis. It had no effect on  early multi- 
plication of M. avium complex. 
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INTRODUCTION 
Tuberculosis and disseminated Mycobacterium aoinm 
complex (MAC) infection are the two major bacterial 
infections in patients with AIDS [1-31. For patients 
infected with multiresistant Mycobacterium tuberculosis, 
only a limited number of alternative chemotherapeutic 
regimens is available; none of them is very effective, and 
the mortality is high [4,5]. MAC is far less susceptible 
than Al .  tuberculosis to chemotherapy, and the list of 
antimicrobial agents active in vivo against MAC is very 
short [6]. Therefore, new, eflective treatments, includ- 
ing non-chemotherapeutic approaches such as cytokine 
therapy, for both infections aire needed. 
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The cytokine interleukin-12 (IL-12) is produced 
by phagocytic cells and is thought to be a principal 
regulator of interferon-? (IFN-y) and T-cell subsets in 
vivo, and may be useful for the treatment of infections 
caused by intracellular pathogens such as hf. triberculosis 
and MAC [7]. We designed mouse experiments to 
evaluate the likely impacts of IL-12 on multiplication 
of both pathogens, and the possible synergistic effects 
between IL-12 and chemotherapy in the chronic 
tuberculosis model. 
MATERIALS AND METHODS 
Mice 
For the tuberculosis experiments, 255 1-5 week old 
female Swiss imrnunocompetent (normal) mice were 
purchased from the Janvier Breeding Center, le Genest- 
Isle, France. The results of our  earlier experiments 
indicate that the Swiss normal mice from the center are 
highly susceptible to intravenous infection of 0.1 mg 
(about 10' CFU) M.  tiiberculosis H37Rv and that the 
great majority of mice died within 30 days after 
inoculation [8,9]; on the other hand, they developed a 
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highly reproducible, chronic and non-fatal infection 
after inoculation with 0.001 mg (about 5X1O3 to 
1 X lo4 CFU) of H37Rv [8,10]. For the MAC experi- 
ments, 295 4-6-week-old female beige (C57BL/6J 
bgJ/bgJ) mice were purchased from the Jackson 
Laboratory, Bar Harbor, Maine. Before infection with 
MAC, the beige mice were housed in our animal 
facilities for another 4 weeks until their body weights 
reached 18-20 g. 
Bacteria and infections 
The virulent H37Rv strain of M .  tuberculosis and the 
101 strain [I11 of MAC were passaged regularly 
through Swiss normal or beige mice, respectively, in 
our laboratory. In the current experiments, each mouse 
was infected intravenously with 0.5 mL of a diluted 
Dubos broth containing 5.5X103 CFU of strain 
H37Rv for tuberculosis experiments or 1.87X lo7 
CFU of strain 101 for MAC experiments, as deter- 
mined by viable counts on, respectively, Lowenstein- 
Jensen or 10% OADC-enriched 7Hl l  agar medium. 
For the H37Rv strain, the minimal inhibitory con- 
centrations were 0.1 mg/L of isoniazid and 0.25 mg/L 
of rifampin on 7H11 agar medium, and 10 mg/L 
of pyrazinamide on Lowenstein-Jensen medium at 
pH 5.5. 
Treatment 
Purified murine recombinant IL-12 was prepared as 
described previously [12]. To evaluate the relationships 
between the doses of IL-12 and its toxicity and efficacy, 
high (1.0 pg), medium (0.2 pg) and low (0.04 pg) 
doses of IL-12, diluted with 1% mouse serum in 
phosphate-buffered saline (PBS), were tested among 
M. tuberculosis-infected mice. In addition, three groups 
of 10 non-infected mice were also injected with either 
high or medium doses of IL-12 or 1% mouse serum in 
PBS for five consecutive days per week for 2 weeks. 
For tuberculosis experiments, 10 of the 225 
infected mice were sacrificed at day 1 (Dl) after 
inoculation to establish the baseline data, and the 
remaining mice were allocated randomly to an 
untreated control group of 45 mice and 10 treated 
groups of 10-20 mice each. Among the three treated 
groups with 10 mice each, subcutaneous administration 
on five consecutive days per week with one of the three 
different (high, medium and low) doses of IL-12 was 
begun at D1, and continued up to D12 (i.e. after 10 
doses). The mice were sacrificed at D14, together with 
15 untreated control mice. Among the remaining seven 
treated groups with 20 mice each, no treatment was 
given up to D14; and then they were treated with either 
chemotherapy alone, or subcutaneous administration 
with one of the three different doses of IL-12 alone, or 
chemotherapy plus one of the three different doses of 
IL-12. Chemotherapy was administered on six 
consecutive days per week through an esophageal 
cannula, and each dose contained the following three 
drugs: isoniazid 25 mg/kg of body weight, rifampin 
10mg/kg and pyrazinamide 150 mg/kg. At D28 and 
D42, or after 10 or 20 doses of IL-12, 10 mice fiom 
each treated group and 15 mice fiom the untreated 
control group were sacrificed. 
For the MAC experiment, 10 infected beige mice 
were sacrificed at D1, and the remaining mice were 
allocated randomly to an untreated control group of 
265 mice and an IL-12-treated group of 20 mice. 
Subcutaneous administration of IL-12 was initiated at 
D1, at a medium dose (0.2 &mouse), and continued 
for five consecutive days per week. At D14, i.e. after 10 
injections of IL-12 in the treated group, 10 mice were 
sacrificed from either group. Although we intended 
to continue the IL-12 administration for four weeks, 
because eight of the remaining 10 treated mice died 
between D14 and D21, the two surviving treated mice 
and three untreated controls were sacrificed at D21, i.e. 
after 15 injections of IL-12 in the treated group. 
Assessment of results 
The major parameters for assessing the effectiveness of 
treatment and the severity of infection were: (1) serum 
IFN-y and IgG isotypes; (2) the number of CFUs in 
the spleens and lungs; (3) gross lung lesions (for 
tuberculosis experiments only); and (4) spleen weights. 
The severity of gross lesions in the lungs was scored 
from 0 to 2+,  with the latter referring to a lung exten- 
sively infiltrated with tubercles [9,13]. The adverse 
effects or toxicity of IL-12 were judged by the mortality 
of mice, infected or non-infected, treated with IL-12. 
Serum IgG measurements 
To demonstrate that IL-12 was active and behaving as 
expected in promoting a type 1 T-cell response, IFN-y, 
IgGl and IgG2, serum levels were assessed [7]. IFN-y 
was quantified by ELISA using monoclonal antibodies 
AN-18 [14] and XMG1,2 [15]. Total serum IgGl and 
IgG2 were quantified by ELISA using polyclonal anti- 
mouse IgGl and antimouse IgGza as capture and detec- 
tion antibodies (Southern Biotechnology Associates, 
Inc., Birmingham, Alabama, USA). 
Enumeration of CFUs in the organs 
At the time of sacrifice or autopsy, the organs were 
removed aseptically and homogenized by a standard 
procedure [16], and the suspensions were made up to 
3.5 mL for each organ. At least four serial IO-fold 
dilutions of the suspensions were plated in quadrupli- 
cate on Lowenstein-Jensen medium (for tuberculosis 
Loun is  e t  al:  Impac t  of  I L - 1 2  o n  m u l t i p l i c a t i o n  of M. tubercu los is  and  M.  a v i u m  comp lex  3 3 3  
experiments) or in duplicate on 10% OADC-enriched 
7 H l l  agar medium (for h4AC experiments). The 
results of the cultures were recorded after incubation at 
37°C for six weeks on Lowenstein-Jensen medium and 
for two weeks on 7H11 agar medium. 
Statistical analysis 
Results were analyzed by the Student t-test and Fisher‘s 
exact probability calculation; differences were con- 
sidered significant at the 95% level of confidence. 
RESULTS 
Effects of 11-12 in M. tu~erculosis-infected mice 
Analysis of serum IFN-y, lgGt and /gGza levels 
IL-12 administration induced a type 1 T-cell response, 
as demonstrated by the increased levels of serum IFN-7 
and of IgGz, antibody isotype compared to IgGl 
antibody isotype [7]. Serum IFN-y levels were detected 
in IL-12-treated mice on day 14 and day 28, but not in 
mice that had not received IL-12 (data not shown). On 
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Figure 1 Serum concentrations (mg/L) of IgGl and IgGza (a) and the ratios of serum IgG2, versus IgGi (b) in mice at day 
42 after infection with M. tuberculosis. Treatment began at day 14. IL-12 was injected subcutaneously five times weekly; 
high-, medmm- and low-dose IL-12 refer, respectively, to 1.0, 0.2 and 0.04 pg/mouse per injection; chemotherapy was 
given six times weekly by gavage, and each dose consisted of isoniazid 25 mg/kg of body weight, rifampin 10 mg/kg and 
pyrozinamide 150 mg/kg. Each bar represents the mean of 6-10 mice, except for the untreated control group, which 
contained 15 mice. Error bars represent the standard deviations of the serum concentration in each group. 
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day 42, an increase in serum IgG2, level and a decrease 
in serum IgGl level were observed in infected mice 
treated with IL-12 as compared with untreated 
controls, both changes displaying a tendency for IL-12 
dose-dependency; in mice treated with high doses of 
IL-12 alone, there was a 3-4-fold increase in IgG2, level 
and same degree of decrease in IgGl level (Figure la). 
Consequently, there was an IL-12 dose-dependent 
increase in the ratio of IgGz, versus IgGl among these 
treated mice (Figure lb). Simultaneous administration 
of chemotherapy did not alter the type 1 response 
induced by IL-12 in mice. 
Organ CFU counts 
The mean (loglo) CFU counts in the spleens and lungs 
from control and all treated groups are presented in 
Figure 2. In control mice, the infection proceeded as 
expected. At the first day (Dl) after inoculation, the 
mean CFU counts in spleens and lungs of untreated 
control mice were, respectively, 2.95k0.07 and 2.32k 
0.23; the mean number per organ increased 6om 2.5 
to 3 loglo during the initial 14 days after inoculation, 
and then slightly decreased or remained the same up to 
the end of the experiment, D42 (Figures 2a and 2b). 
In the groups treated with IL-12 from D1 of 
infection, at D14 the mean numbers of CFUs of all IL- 
12 treated groups were significantly smaller than that of 
control mice (p<O.Ol orp<0.05), except in the lungs 
of mice treated with low doses of IL-12 alone (Figures 
2a and 2b). In both organs, a trend of the CFU count 
towards IL-12 dose-dependence was observed. The 
difference between the CFU counts in mice treated 
with high- or medium-dose IL-12 was not statistically 
8 k? 7 3  
significant, but both were significantly smaller than 
those in mice treated with low-dose IL-12 (p<O.Ol or 
p<O.O5). 
Despite the significant activity observed when 
treatment was adrmnistered over D1 to D14, no impact 
of IL-12 on multiplication of M. tuberculosis was 
observed either in the spleens or in the lungs if the 
treatment began at D14 and continued up to D42. On  
D42, the mean numbers of CFUs in mice treated with 
any dose of IL-12 alone did not d&er significantly from 
that in control mice in the spleens (Figure 2a), and were 
even slightly greater than that in the control mice in the 
lungs (p<O.Ol orp<0.05) (Figure 2b). Compared with 
pretreatment values, four weeks of chemotherapy alone 
reduced the CFU count by more than 2 loglo in both 
organs; none of the combinations with IL-12 signifi- 
cantly enhanced the bactericidal activity of chemo- 
therapy (Figure 2). 
Gross lung lesions 
By D14, 1+ lesions occurred rarely, 0-2 out of 10-15 
mice per group, in the untreated control or IL-12- 
treated mice, and no 2+ lesions were detected. Lung 
lesions developed rapidly after D14 in untreated 
controls and mice that had been treated with IL-12 
alone regardless of dosage: by D28, lung lesions were 
observed in almost all of the mice, and 2+ lesions were 
detected in more than half'of the lungs in each group; 
by D42, 2+ lesions occurred in the great majority of 
lungs. However, by D28 or D42, only 1 + lesions were 
detected in a small percentage of mice treated with 
chemotherapy, with or without co-administration of 
IL-12, and no 2+ lesions were detected in these mice. 
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Figure 2 The mean numbers (loglo) of CFUs in the spleens (a) and lungs (b). Mice were each infected intravenously with 
strain H37Rv at DO, and treatment was begun either on day 1 or day 14. Chemotherapy with isoniazid, rifampin and 
pyrazinamide (Rx) was given six times weekly by gavage, and each dose consisted of isoniazid 25 mg/kg, rifampin 10 mg/kg 
and pyrazinamide 150 mg/kg; IL-12 was administered by subcutaneous injection five times weekly in high (1.0 pg), medium 
(0.2 pg) or low (0.04 pg) dose. Each point represents the mean of 6-10 mice, except for the untreated control group, which 
contained 15 mice. On D42, the point of the control group matched that of the low IL-12 alone group, and that of the Rx 
group matched that of the high IL-12+ Rx group in the spleens; and the point of the Rx group matched that of the low 
IL-12+ R x  group in the lungs. 
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Therefore, IL-12 alone could not prevent the develop- 
ment of gross lung lesions caused by M. tuberculosis 
infection, whereas chemotherapy could; in addition, 
IL-12 did not enhance the effect of chemotherapy in 
preventing the development of gross lung lesions. 
Spleen weights 
The spleen weights are normally taken as a measure of 
the level of experimental M. tuberculosis infection in 
mice [8,13]. This indicator is complicated in the 
current study by the known effect of IL-12 in inducing 
a dose-dependent splenomegaly [12]. 
The mean spleen weight significantly increased in 
infected but untreated control mice during the initial 
14 days d e r  inoculation (pCO.01) (Figure 3a), and 
then remained the same up to D42 (p>O.O5) (Figure 
3b). Sipficantly, the increase of the mean number of 
spleen CFUs was observed only between D1 and D14 
in this group (see above), indicating that in control mice 
the splenomegaly was mainly due to the multiplication 
of M. tuberculosis. 
Nevertheless, the mean spleen weights of non- 
infected mice that had been treated for 2 weeks with 
high- or medium-dose IL-12 were also significantly 
increased (Figure 3a), and did not differ significantly 
h m  those of infected and IL-12-treated or untreated 
mice. Between D14 and D42, although the mean 
spleen weight of the infected but untreated control 
mice remained constant, there was a further IL-12 
dose-dependent increase in spleen weights among 
infected and IL-12-treated mice (Figure 3b). By D42, 
the mean spleen weight in infected mice that had been 
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Figure 3 The mean spleen weights in M. tuberculosis-infected (solid lines) and non-infected (dotted lines) mice. Mice were 
infected intravenously with st ra in  H37Rv at DO, and treatment began either at day 1 (a) or at day 14 @). High, medium and 
low IL-12 refer, respectively, to the injection of 1.0, 0.2 and 0.04 pg of IL-12 per mouse five times weekly. Chemotherapy 
(Rx) w a s  given six times weekly by gavage. and each dose consisted of isoniazid 25 mg/kg, rifampin 10 mg/kg and 
pyrazinamide 150 mg/kg. Each point represents the mean of &lo mice, except for the untreated control group, which 
contained 15 mice. 
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treated with high-dose IL-12 was 10 times greater than 
that of normal spleens and four times greater than that 
of untreated controls. These results confirmed the 
previous observation [12] that IL-12 injection alone 
may cause splenomegaly. 
The spleen weight in mice treated with chemo- 
therapy alone progressively decreased between D14 and 
D42 ( p <  0.01), again demonstrating the correlation 
between the number of M. tuberculosis organisms and 
the extent of splenomegaly. On the other hand, the 
mean spleen weights in mice treated with IL-12 plus 
chemotherapy were always intermediate between those 
in mice treated with chemotherapy alone and those 
treated with the same dose of IL-12 alone, suggesting 
that the splenomegaly in such mice was a consequence 
of the combination of reduction by chemotherapy and 
increase through IL-12 administration. 
Adverse effects of IL- 12 
During the initial 14 days of IL-12 administration, 
mortality was observed in four of 10 and two of 10 
infected mice treated, respectively, with high or medium 
doses of IL-12, and three of 10 non-infected mice treated 
with high doses of IL-12; no mortality was observed in 
infected but untreated controls, infected mice that had 
been treated with low doses of IL-12, or non-infected 
mice that had been treated with medium or low doses 
1 
of IL-12 (Table 1). Thus, it is clear that the mortality was 
caused by the toxicity of IL-12, and 2 weeks (10 
injections) of hgh-dose IL-12 was toxic to the mice. 
Effects of 11-12 in MAC-infected beige mice 
The mean spleen weight was only 67? 18 mg at D1, 
increased significantly in untreated control mice and 
reached 592r198  mg at D14; however, in IL-12- 
treated mice it was 884?94 mg at D14, significantly 
Table 1 Mortality of mice during the initial 14 days of IL- 
12 administration 
Grouvl n Death 
M. tuberculosis-infectedb 
Untreated control 15 
High IL-12 10 
Medium IL-12 10 
Low IL- 12 10 
Untreated control 
9 1 IL-12treated 
Non-infected 
High IL-I2 10 3 
Memum IL-12 10 0 
1% serum PBS 10 0 
"IL-I2 was injected five times weekly and began at D1 after 
infection. High-, medium- and low-dose IL-12 refer, respectively, 
to 1 .O, 0.2 and 0.04 pg/mouse per injection. 
bMice were each infected intravenously with 5 X lo3 CFU of the 
virulent strain H37Rv at DO. 
....o. ' Untreated control 
T 
4 1  I I i 
0 7 14 21 
Days after inoculation 
Figure 4 Mean numbers of CFUs in the spleens (solid lines) and lungs (dotted lines) of untreated control and IL-12-treated 
beige mice. Mice were inoculated intravenously with MAC strain 101 on DO, and treatment began on D1. IL-12 was 
administered by subcutaneous injection five times weekly at 0.2 pg/mouse per injection. CFUs were enumerated on 10% 
OADC-enriched 7H11 agar medium. Each point represents the mean of 10 samples, except the points of D21 for three 
samples (including the organs from a treated mouse that &ed on the morning of D21). Error bars represent the standard 
deviations of the untreated control mice. 
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greater than that in untreated controls (p<0.01), again 
demonstrating the immune activating effect of IL-12 at 
the applied dose. 
Figure 4 shows that MAC progressively multiplied 
in both spleens and lungs of untreated control mice. 
The growth curves of MAC in the IL-12-treated mice 
were almost identical to those of control mice, indicat- 
ing that treatment with IL-12 did not affect the, multi- 
plication of MAC in the infected beige mice. 
During the initial 14 days after inoculation, no 
mortality was observed either in the untreated control 
group or in the IL-12-treated group. However, eight 
(80%) of the 10 treated mice that remained after the 
sacrifice on D14 died between D14 and D21, while 
only 22 (8.6%) of the 255 control mice died during the 
same period. The mortality rate between D14 and D21 
in the IL-12-treated mice was significantly greater than 
that of control mice (p<0.01), indicating that when 
IL-12 was injected in more than 10 doses, even its 
medium dosage was quite toxic to the MAC-infected 
beige mice. 
DISCUSSION 
In the current experiments, Swiss mice were infected 
intravenously with a small inoculum, about 5 x lo3 
CFU per mouse, of virulent Ad. tuberculosis; as expected, 
they only developed a chronic and non-fatal infection 
[8,10]. However, before t:he protective immunity 
matures at about D 14 after infection, the organisms 
multiply almost freely [&lo], which provides a good 
opportunity to assess whether IL-12 alone had any 
effect on the multiplication of M.  tuberculosis. In mice 
that had been injected subcutaneously with IL-12 alone 
on five consecutive days per week at doses ranging from 
0.04 to 1 .0 pg/mouse, multiplication of M.  titberculosis 
was slightly suppressed only if the treatment began on 
the first day (D1) after infection, but no such suppres- 
sion was observed if the treatment began at D14. In 
addition, combination with IL-12 did not enhance the 
bactericidal activity of chemctherapy if both treatments 
began at D14. Therefore, it is reasonable to believe that 
administration of IL-12 may accelerate the develop- 
ment of protective immunity and thereby limit the 
multiplication of M.  tuberculosis; however, such an effect 
was no longer exerted by IL-12 in mice once the 
protective immunity had already matured, i.e. at D14 
after infection. 
To date, there are two publications relating to the 
role of exogenous administration of IL-12 in M .  tuber- 
culosis infection in mice [17,'18]. Despite differences in 
the mouse strain, the M.  tuberculosis strain, and the 
mode of administration of IL-12, our results are similar. 
Cooper et al. reported that in M. tuberculosis-infected 
C57BL/6 or beige mice, administration of IL-12, 
which was injected intraperitoneally at a dose of 
0.4 &mouse every other day beginning on D1 after 
infection, resulted in a transient increase of resistance to 
M.  tuberculosis infection, as the mean number of CFUs 
in the organs was smaller in the IL-12-treated mice 
than in the saline-treated controls at D10 but did not 
differ significantly at  D30 [17]. In addition, administra- 
tion of IL-12 also slightly increased the resistance in M. 
tuberculosis-infected T-cell-deficient mice, as the sur- 
vival of severe combined immunodeficiency (SCID) 
mice was extended and a degree of reduction of the 
bacterial loads was observed in the BALB/c nude mice 
[17]. Flynn et a1 reported that in M. tuberculosis-infected 
BALB/c mice, a mouse strain highly susceptible to 
virulent M. tuberculosis infection, administration of IL- 
12, starting at the date of infection at 0.5 pg/mouse 
intraperitoneally and continuing for five consecutive 
days per week for 2 weeks, doubled the mean survival 
time and diminished the bacterial loads in the spleens 
and livers up to D118 after infection, as compared with 
the PBS-treated mice [18]. Similar treatment with IL- 
12 also reduced the bacterial loads in IFN-y receptor 
knock-out mice with a C57BL/6 background, which 
were as resistant to M.  tuberculosis infection as were 
C57BL/6 mice, but the effect in IFN-y receptor knock- 
out mice was not as pronounced as in BALB/c mice 
The results from all three groups clearly indicate 
that administration of IL-12 has the ability to limit, to 
various degrees, the multiplication of M. ttrberculosis in 
mice with various genetic backgrounds. However, its 
effect is modest and transient. According to Flynn et al, 
who obtained the most favorable effect of IL-12 among 
the three studies, all the IL-12-treated mice succumbed 
to the infection by D120, and there was almost no 
effect of IL-12 on multiplication of M.  tubercirlosis in the 
lungs of IL-12-treated mice [18]. Furthermore, our 
work indicates that combination with IL-12 does not 
enhance the bactericidal activity of chemotherapy. 
Therefore, the prospects of using IL-12 for the treat- 
ment of human tuberculosis appear to be poor. 
To protect mice from MAC infection, others have 
attempted to stimulate the natural killer (NK) cells in 
mice; the results were negative with injection of 
poly(1:C) [19] but positive with injection ofIL-12 [20]. 
However, the latter results were obtained in BALB/c 
mice, a mouse strain far less susceptible to MAC than 
C57BL/6 [21]; in the IL-12 study, the multiplication 
of MAC was less than one order of magnitude between 
D1 and D35 in infected but untreated BALWc mice 
[20]. Although the potential therapeutic effects of other 
cytokines, such as tumor necrosis factor (TNF), IL-2 
and granulocyte-macrophage colony-stimulating factor 
1181. 
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(GM-CSF), have been tested in MAC-infected beige 
mouse model [22,23], surprisingly, no information is 
available on the activity of IL-12 against MAC in beige 
mice. As shown in Figure 4, MAC multiplied progres- 
sively in the spleens or lungs of untreated beige mice, 
increasing by more than two orders of magnitude 
w i t h  3 weeks, indicating that the beige mice were 
highly susceptible to MAC. Because in beige mice the 
growth curves of MAC in the organs of IL-12 treated 
mice were almost identical to those of untreated con- 
trols, one may conclude that IL-12, at least at the dose 
applied in the current experiment, did not show any 
inhibitory effect on multiplication of MAC in the beige 
mouse model. 
Based on the analysis of the cellular composition in 
the spleens, it was concluded that the dose of 1.0 pg/ 
mouse per day was too toxic, and the maximum dose 
for mouse experiments should be 0.4 pg/mouse every 
other day [17]. Since we have observed that the mort- 
ality was 30-40% among Swiss mice during the course 
of subcutaneous injection of IL-12 at a dose of 1.0 
pg/mouse on five consecutive days per week for 2 
weeks, the toxic effects at this higher dose were 
confirmed. The finding that 80% of beige mice died 
between 11 and 15 injections with IL-12 at dose of 
0.2 pg/mouse suggests that the MAC-infected beige 
mice, just like other mice with a C57BL/6 background 
[18], are more susceptible to the toxic effects of IL-12. 
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